NTRK fusion in papillary thyroid carcinoma (~1-2% sporadic, higher in radiation-induced d...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-NTRK-FUSION-THYROID-PAPILLARY |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-THYROID-PAPILLARY |
| Sources | SRC-FDA-CDS-2026 |
Actionability Facts
| Biomarker | BIO-NTRK-FUSION |
|---|---|
| Variant | NTRK1/3 fusion (rare in PTC, ~1-2%; enriched in radiation-induced PTC) |
| Disease | DIS-THYROID-PAPILLARY |
| ESCAT tier | IA |
| Recommended combinations | larotrectinib monotherapy (RAI-refractory advanced disease), entrectinib monotherapy |
| Evidence summary | NTRK fusion in papillary thyroid carcinoma (~1-2% sporadic, higher in radiation-induced disease — Chernobyl cohorts). Larotrectinib and entrectinib are FDA tumor-agnostic for NTRK-fusion solid tumors. PTC subset of NAVIGATE / STARTRK-2 demonstrates durable responses in RAI-refractory disease. |
Notes
ESCAT IA. OncoKB Level 1. RAI ablation remains 1L for differentiated PTC. NTRK-TKI is for RAI-refractory progressive disease. Detection: RNA-NGS preferred. Source-gap: SRC-NCCN-THYROID-2025 placeholder.
Used By
No reverse references found in the YAML corpus.